CI
VRTX icon

Cowen Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Cowen Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-9,500
Closed -$706K – 240
2013
Q4 		$706K Sell
9,500
-8,500
-47% -$592K 0.12% 142
2013
Q3 		$1.36M Sell
18,000
-2,000
-10% -$159K 0.2% 76
2013
Q2 		$1.6M Buy
+20,000
New +$1.47M 0.16% 91

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cowen Inc's VRTX Position: Q1 2014 in Review

Cowen Inc sold out of Vertex Pharmaceuticals (VRTX) in Q1 2014, closing a stake of 9,500 shares — an estimated $706K sold.

Cowen Inc first reported a position in VRTX in Q2 2013 and held it in 3 quarters. The position peaked at $1.6M in Q2 2013. 395 funds tracked by Wall St. Rank hold VRTX as of Q1 2014.

  • Cowen Inc reported no remaining Vertex Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Cowen Inc sold 9,500 Vertex Pharmaceuticals shares in Q1 2014, an estimated $706K.
  • Cowen Inc first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Cowen Inc's Vertex Pharmaceuticals position peaked at $1.6M in Q2 2013.
  • 395 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2014.

Based on Cowen Inc's 13F filing for Q1 2014, filed 16 May 2014.